Advertisement
Screener

INNOVIVA, INC. (INVA) Increase (Decrease) in Deferred Charges

2.8 / 5 stars · 68/120 Roast Me

INNOVIVA, INC. Increase (Decrease) in Deferred Charges

INNOVIVA, INC. (INVA) reported Increase (Decrease) in Deferred Charges of $5.00 thousand for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-05.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredCharges · last filed 2015-11-05

  • INNOVIVA, INC. increase (decrease) in deferred charges for the quarter ending 2015-09-30 was $2.00K.
  • INNOVIVA, INC. increase (decrease) in deferred charges for the quarter ending 2015-06-30 was -$13.00K.
  • INNOVIVA, INC. increase (decrease) in deferred charges for the quarter ending 2015-03-31 was $16.00K.
  • INNOVIVA, INC. increase (decrease) in deferred charges for the quarter ending 2014-12-31 was -$51.00K.
  • INNOVIVA, INC. increase (decrease) in deferred charges for fiscal 2014 was -$275.00K, a 191.97% decline from fiscal 2013.
  • INNOVIVA, INC. increase (decrease) in deferred charges for fiscal 2013 was $299.00K, a 59.97% decline from fiscal 2012.
  • INNOVIVA, INC. increase (decrease) in deferred charges for fiscal 2012 was $747.00K.
  • INNOVIVA, INC. increase (decrease) in deferred charges for fiscal 2011 was -$2.43M.
Period endIncrease (Decrease) in Deferred Charges 3 monthIncrease (Decrease) in Deferred Charges 6 monthIncrease (Decrease) in Deferred Charges 9 monthIncrease (Decrease) in Deferred Charges 12 month
2015-09-30$2.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05
-$11.00K
derived: sum of 2 quarters · filed 2015-11-05
$5.00K
10-Q · filed 2015-11-05
-$46.00K
derived: sum of 4 quarters · filed 2015-11-05
2015-06-30-$13.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06
$3.00K
10-Q · filed 2015-08-06
-$48.00K
derived: sum of 3 quarters · filed 2015-08-06
-$89.00K
derived: sum of 4 quarters · filed 2015-11-05
2015-03-31$16.00K
10-Q · filed 2015-05-08
-$35.00K
derived: sum of 2 quarters · filed 2015-05-08
-$76.00K
derived: sum of 3 quarters · filed 2015-11-05
-$143.00K
derived: sum of 4 quarters · filed 2015-11-05
2014-12-31-$51.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27
-$92.00K
derived: sum of 2 quarters · filed 2015-11-05
-$159.00K
derived: sum of 3 quarters · filed 2015-11-05
-$275.00K
10-K · filed 2015-02-27
2014-09-30-$41.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05
-$108.00K
derived: sum of 2 quarters · filed 2015-11-05
-$224.00K
10-Q · filed 2015-11-05
-$341.00K
derived: sum of 4 quarters · filed 2015-11-05
2014-06-30-$67.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06
-$183.00K
10-Q · filed 2015-08-06
-$300.00K
derived: sum of 3 quarters · filed 2015-08-06
-$260.00K
derived: sum of 4 quarters · filed 2015-08-06
2014-03-31-$116.00K
10-Q · filed 2015-05-08
-$233.00K
derived: sum of 2 quarters · filed 2015-05-08
-$193.00K
derived: sum of 3 quarters · filed 2015-05-08
-$19.00K
derived: sum of 4 quarters · filed 2015-05-08
2013-12-31-$117.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27
-$77.00K
derived: sum of 2 quarters · filed 2015-02-27
$97.00K
derived: sum of 3 quarters · filed 2015-02-27
$299.00K
10-K · filed 2015-02-27
2013-09-30$40.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04
$214.00K
derived: sum of 2 quarters · filed 2014-11-04
$416.00K
10-Q · filed 2014-11-04
$617.00K
derived: sum of 4 quarters · filed 2015-02-27
2013-06-30$174.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
$376.00K
10-Q · filed 2014-08-07
$577.00K
derived: sum of 3 quarters · filed 2015-02-27
$779.00K
derived: sum of 4 quarters · filed 2015-02-27
2013-03-31$202.00K
10-Q · filed 2014-05-07
$403.00K
derived: sum of 2 quarters · filed 2015-02-27
$605.00K
derived: sum of 3 quarters · filed 2015-02-27
$806.00K
derived: sum of 4 quarters · filed 2015-02-27
2012-12-31$201.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27
$403.00K
derived: sum of 2 quarters · filed 2015-02-27
$604.00K
derived: sum of 3 quarters · filed 2015-02-27
$747.00K
10-K · filed 2015-02-27
2012-09-30$202.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01
$403.00K
derived: sum of 2 quarters · filed 2013-11-01
$546.00K
10-Q · filed 2013-11-01
$453.00K
derived: sum of 4 quarters · filed 2014-03-03
2012-06-30$201.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01
$344.00K
10-Q · filed 2013-08-01
$251.00K
derived: sum of 3 quarters · filed 2014-03-03
-$153.00K
derived: sum of 4 quarters · filed 2014-03-03
2012-03-31$143.00K
10-Q · filed 2013-05-01
$50.00K
derived: sum of 2 quarters · filed 2014-03-03
-$354.00K
derived: sum of 3 quarters · filed 2014-03-03
-$1.51M
derived: sum of 4 quarters · filed 2014-03-03
2011-12-31-$93.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
-$497.00K
derived: sum of 2 quarters · filed 2014-03-03
-$1.65M
derived: sum of 3 quarters · filed 2014-03-03
-$2.43M
10-K · filed 2014-03-03
2011-09-30-$404.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31
-$1.56M
derived: sum of 2 quarters · filed 2012-10-31
-$2.34M
10-Q · filed 2012-10-31
-$2.15M
derived: sum of 4 quarters · filed 2013-02-26
2011-06-30-$1.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01
-$1.93M
10-Q · filed 2012-08-01
-$1.74M
derived: sum of 3 quarters · filed 2013-02-26
-$2.45M
derived: sum of 4 quarters · filed 2013-02-26
2011-03-31-$776.00K
10-Q · filed 2012-05-02
-$585.00K
derived: sum of 2 quarters · filed 2013-02-26
-$1.29M
derived: sum of 3 quarters · filed 2013-02-26
2010-12-31$191.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26
-$515.00K
derived: sum of 2 quarters · filed 2013-02-26
-$1.45M
10-K · filed 2013-02-26
2010-09-30-$706.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02
-$1.64M
10-Q · filed 2011-11-02
2010-06-30-$931.00K
10-Q · filed 2011-08-03
2009-12-31$709.00K
10-K · filed 2012-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10